A number of other brokerages have also commented on MESO. Cantor Fitzgerald set a $23.00 price target on shares of Mesoblast and gave the company a buy rating in a research note on Monday, October 1st. ValuEngine upgraded shares of Mesoblast from a hold rating to a buy rating in a research note on Wednesday, September 26th. Zacks Investment Research upgraded shares of Mesoblast from a sell rating to a hold rating in a research note on Wednesday, August 1st. Maxim Group reiterated a buy rating and issued a $16.00 price target on shares of Mesoblast in a research note on Friday, October 12th. Finally, TheStreet upgraded shares of Mesoblast from a d+ rating to a c- rating in a research note on Monday, October 1st. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $14.13.
MESO traded down $0.05 on Thursday, reaching $6.35. The company had a trading volume of 31,751 shares, compared to its average volume of 67,562. Mesoblast has a fifty-two week low of $4.74 and a fifty-two week high of $8.78. The firm has a market cap of $635.65 million, a P/E ratio of -10.08 and a beta of 1.99. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.21 and a current ratio of 4.21.
An institutional investor recently bought a new position in Mesoblast stock. Jane Street Group LLC acquired a new stake in Mesoblast limited (NASDAQ:MESO) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 17,731 shares of the company’s stock, valued at approximately $102,000. 2.76% of the stock is currently owned by hedge funds and other institutional investors.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Read More: Ex-Dividend
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.